Medical device company developing therapeutic devices for cardiovascular diseases.
Orchestra BioMed Holdings, Inc. is a pioneering therapeutic device company focused on advancing treatments and products designed to combat cardiovascular diseases. Based in New Hope, Pennsylvania, Orchestra BioMed has garnered acclaim for its innovative developments in bioelectronic therapies and drug/device combination products.
Among its notable innovations is the BackBeat Cardiac Neuromodulation Therapy (CNT), a patented bioelectronic treatment tailored for hypertension management. This intelligent therapy system represents a significant advancement in cardiovascular care, aiming to provide effective treatment options beyond traditional approaches.
The company also boasts the Virtue SAB, a patented drug/device combination product designed to address arterial disease. Additionally, Orchestra BioMed offers the Virtue SEB, a drug-eluting balloon angioplasty system intended for treating coronary artery disease, underscoring its commitment to enhancing patient outcomes through cutting-edge medical technologies.
Orchestra BioMed Holdings, Inc. has forged strategic partnerships with industry leaders such as Medtronic to further develop and commercialize its innovations. This collaboration focuses on expanding the application of BackBeat CNT as a potential treatment for hypertension in patients eligible for cardiac pacemaker therapy, reflecting the company's dedication to advancing cardiovascular therapies through strategic alliances and ongioing research and development efforts.